trending Market Intelligence /marketintelligence/en/news-insights/trending/a8o-ervm7i2mxn7qt6lvfg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Helix, ProMab to develop cell-based treatment for multiple myeloma

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Helix, ProMab to develop cell-based treatment for multiple myeloma

Helix BioPharma Corp. has completed an agreement with ProMab Biotechnologies, Inc. to develop a cell-based therapy to prevent and treat solid tumors.

The Richmond, Ontario-based company will collaborate with ProMab to develop chimeric antigen receptor T cell, or CAR-T, technologies for certain hematological malignancies.

The identified treatment will be developed for multiple myeloma, a type of blood cancer. Helix retains the commercial rights to the CAR-T cell therapy in Canada and Europe.

SNL Image

The program intends to start human trials by early 2019.

Helix said it continues to prioritize its DOS47 drug development, particularly its clinical L-DOS47 and V-DOS47 preclinical programs, both for treating cancers.